Program
zanzalintinib
Also written as “Zanzalintinib” and “XL092”.
Its studies are mostly in Carcinoma, Renal Cell · Neoplasms · Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Adenoma, Islet Cell, led by 3 companies.
Drug pageZanzalintinib: every studyAll 50 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Exelixisits history only | 1312 open or running | phase 3since Jun 16, 2022 | Feb 15, 2019 | Dec 15, 2026phase 3 · NCT05678673 |
| Merckits history only | 33 open or running | phase 3since Nov 7, 2025 | Jun 25, 2025 | Nov 27, 2030phase 3 · NCT07489495 |
| Hoffmann-La Rocheits history only | 10 open or running | phase 2since Nov 7, 2017 | Nov 7, 2017 | none ahead |
Also a collaborator on its studies: Bristol-Myers Squibb and Arcus Biosciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Nov 7, 2017.
- Jun 16, 2022Phase 3 study in Colorectal NeoplasmsExelixis · NCT05425940 · 901 enrolled · United States, Australia, Belgium and more
- Jul 21, 2022Named zanzalintinibINNProposed as its International Nonproprietary Name in WHO's List 127 · before, XL092
- Dec 23, 2022Phase 3 study in Non-Clear Cell Renal Cell CarcinomaExelixis · NCT05678673 · 317 enrolled · United States, Argentina, Australia and more
- Oct 9, 2023Phase 3 study in Squamous Cell Carcinoma of Head and NeckExelixis · NCT06082167 · 600 enrolled · United States, Argentina, Australia and more
- Dec 19, 2023Phase 1 study in Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid TumorsExelixis · NCT06191796 · 25 enrolled · United States
- Apr 17, 2025Phase 3 study in Adenoma, Islet CellExelixis · NCT06943755 · 440 planned · United States, Australia, Austria and more
- Apr 30, 2025Phase 1 study in Hepatic ImpairmentExelixis · NCT06962332 · 20 planned · United States
- Jun 25, 2025Merck’s first study: phase 2 study in Carcinoma, Renal CellNew to MerckMerck · NCT07049926 · 140 planned · United States, Chile, France and more
- Nov 7, 2025Phase 3 study in Carcinoma, Renal CellMerck · NCT07227402 · 904 planned · United States, Argentina, Australia and more
- Feb 19, 2026Phase 2 study in MeningiomaExelixis · NCT07428616 · 100 planned · United States
- Mar 20, 2026Phase 3 study in Carcinoma, Renal CellMerck · NCT07489495 · 758 planned · United States, Argentina, Australia and more
- May 27, 2026Phase 3 study in NeoplasmsExelixis · NCT07620574 · 5,000 planned · United States
- Aug 3, 2026Phase 3 study in Colorectal NeoplasmsExelixis · NCT07750158 · 600 planned · United States
- Aug 12, 2026Phase 1 study in NeoplasmsExelixis · NCT07773454 · 18 planned
- Sep 22, 2026Phase 2 study in Squamous Non-Small Cell Lung Cancer (NSCLC)Exelixis · NCT07845786 · 60 planned · United States
Ahead
- Dec 15, 2026Primary completion: phase 3 study in Non-Clear Cell Renal Cell CarcinomaExelixis · NCT05678673
- Jan 31, 2027Primary completion: phase 1 study in Carcinoma, Renal CellExelixis · NCT05176483
- Feb 29, 2028Primary completion: phase 2 study in MeningiomaExelixis · NCT07428616
- Jun 15, 2028Primary completion: phase 2 study in Squamous Non-Small Cell Lung Cancer (NSCLC)Exelixis · NCT07845786
TargetBeta
“An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) hepatocyte growth factor receptor (c-Met; HGFR), vascular endothelial growth factor receptor type 2 (VEGFR2), AXL and MER, ”NCIt, by rule
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07845786Squamous Non-Small Cell Lung Cancer (NSCLC) · United States | 2 | Recruiting | Exelixis | Jun 15, 2028 | 60 |
| NCT07773454Neoplasms | 1 | Not yet recruiting | Exelixis | Jul 31, 2028 | 18 |
| NCT07750158Colorectal Neoplasms · United States | 3 | Recruiting | Exelixis | Apr 5, 2030 | 600 |
| NCT07620574Neoplasms · United States | 3 | By invitation | Exelixis | May 31, 2030 | 5,000 |
| NCT07489495Carcinoma, Renal Cell · United States, Argentina, Australia and more | 3 | Recruiting | Merck | Nov 27, 2030 | 758 |
| NCT07428616Meningioma · United States | 2 | Recruiting | Exelixis | Feb 29, 2028 | 100 |
| NCT07227402Carcinoma, Renal Cell · United States, Argentina, Australia and more | 3 | Recruiting | Merck | Feb 27, 2032 | 904 |
| NCT07049926Carcinoma, Renal Cell · United States, Chile, France and more | 2 | Recruiting | Merck | Oct 26, 2031 | 140 |
| NCT06962332Hepatic Impairment · United States | 1 | Recruiting | Exelixis | Dec 2025 | 20 |
| NCT06943755Adenoma, Islet Cell · United States, Australia, Austria and more | 3 | Recruiting | Exelixis | Jun 30, 2029 | 440 |
| NCT06191796Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors · United States | 1 | Terminated | Exelixis | May 12, 2025 | 25 |
| NCT06082167Squamous Cell Carcinoma of Head and Neck · United States, Argentina, Australia and more | 3 | Active, not recruiting | Exelixis | Aug 2028 | 600 |
| NCT05678673Non-Clear Cell Renal Cell Carcinoma · United States, Argentina, Australia and more | 3 | Active, not recruiting | Exelixis | Dec 15, 2026 | 317 |
| NCT05425940Colorectal Neoplasms · United States, Australia, Belgium and more | 3 | Active, not recruiting | Exelixis | Jun 16, 2026 | 901 |
| NCT05176483Carcinoma, Renal Cell · United States, Australia, Austria and more | 1 | Recruiting | Exelixis | Jan 31, 2027 | 1,394 |
| NCT03845166Neoplasms · United States, Australia, Belgium and more | 1 | Active, not recruiting | Exelixis | Aug 31, 2026 | 325 |
| NCT03337698Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more | 2 | Terminated | Hoffmann-La Roche | Oct 14, 2025 | 314 |
How it is read
Names in the registry
- “Zanzalintinib”, 12 entries
- “XL092”, 4 entries
- “zanzalintinib”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Renal Cell, 6 studies
- Neoplasms, 3 studies
- Colorectal Neoplasms, 2 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Adenoma, Islet Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.